Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

• Main Authors: Lee, Han Chung, Hamzah, Hamizun, Leong, Melody Pui Yee, Md Yusof, Hadri Hadi, Habib, Omar, Zainal Abidin, Shahidee, Mohamed Seth, Eryse Amira, LIm, Siong Meng, Vidyadaran, Sharmili, Mohd Moklas, Mohamad Aris, Abdullah, Maizaton Atmadini, Nordin, Norshariza, Hassan, Zurina, Cheah, Pike See, Ling, King Hwa
• Format: Article
• Published: Springer 2021
• Online Access: http://psasir.upm.edu.my/id/eprint/93421/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884429/
• Institution: Universiti Putra Malaysia

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...